Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation

Roy Vergis, Catherine M Corbishley, Karen Thomas, Alan Horwich, Robert Huddart, Vincent Khoo, Ros Eeles, Matthew R Sydes, Colin S Cooper, David Dearnaley, Chris Parker

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)


Established prognostic factors in localized prostate cancer explain only a moderate proportion of variation in outcome. We analyzed tumor expression of apoptotic markers with respect to outcome in men with localized prostate cancer in two randomized controlled trials of radiotherapy dose escalation.
Original languageEnglish
Pages (from-to)35-41
Number of pages7
JournalInternational Journal of Radiation Oncology, Biology, Physics
Issue number1
Publication statusPublished - 1 Sep 2010


  • Aged
  • Aged, 80 and over
  • Analysis of Variance
  • Androgen Antagonists
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Proteins
  • Neoplasm Staging
  • Prostate-Specific Antigen
  • Prostatic Neoplasms
  • Proto-Oncogene Proteins c-bcl-2
  • Proto-Oncogene Proteins c-mdm2
  • Radiotherapy Dosage
  • Tissue Array Analysis
  • Tumor Suppressor Protein p53

Cite this